Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Moderately to Severely Active Crohn's Disease
NCT03926130Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab in Crohn's disease (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 and Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52. Started Jul 2019; status: completed.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03926130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926130.